Zobrazeno 1 - 4
of 4
pro vyhledávání: '"D. M. Akkurd"'
Publikováno v:
HemaSphere, Vol 6, Pp 965-966 (2022)
Externí odkaz:
https://doaj.org/article/34b755b54ac7456aa81c8b1a8b0bd47e
Publikováno v:
HemaSphere, Vol 6, Pp 2021-2022 (2022)
Externí odkaz:
https://doaj.org/article/92e5f2d9a1c74fb99b395b67b7e5fc2c
Publikováno v:
HemaSphere, Vol 6, Pp 1824-1825 (2022)
Externí odkaz:
https://doaj.org/article/5926c0059af64db6a986cd568f410ca4
Autor:
M A, Ucar, G, Ozet, M B, Koyuncu, M, Sonmez, O, Akidan, M, Ayli, M, Yildirim, M, Pehlivan, D M, Akkurd, H, Sahin, B, Guvenc, V, Okan, E N, Tiftik, A, Akdeniz, H D, Dincyurek, A K, Gunes, S, Dagdas, H I, Acar, H K, Ucar, A, Tombak
Publikováno v:
European review for medical and pharmacological sciences. 25(21)
Relapsed/refractory AML cases are much more resistant to chemotherapy. Venetoclax is a highly sensitive BCL-2 inhibitor. It was aimed to evaluate the effects of venetoclax therapy on real-world R/R AML survival outcomes, the effects of the cytogeneti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3725dd1df6c4b84c4c292f9e77e21ae2
https://pubmed.ncbi.nlm.nih.gov/34787859
https://pubmed.ncbi.nlm.nih.gov/34787859